Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.
Patient Prefer Adherence · 2016
Last updated 2026-05-28In a study of 182 Japanese adults with type 2 diabetes who had never used injectable medications, dosing frequency (44.1%) and delivery system type (26.3%) were the most important factors when choosing between two GLP-1 drugs, dulaglutide and liraglutide. Nausea frequency (15.1%) and hypoglycemia frequency (7.4%) were also considered, while blood sugar control and weight change had minimal impact. A large majority (94.5%) preferred the dulaglutide profile over liraglutide (5.5%).
AI summary of the abstract below.
| Journal | Patient Prefer Adherence, 2016 |
|---|---|
| Citations | 30 |
| Relative citation ratio | 1.44 |
| NIH percentile | 63 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
OBJECTIVE: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients' preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan.
METHODS: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview. The DCE examined the following six attributes of T2DM treatment, each described by two levels: "dosing frequency", "hemoglobin A1c change", "weight change", "type of delivery system", "frequency of nausea", and "frequency of hypoglycemia". Part-worth utilities were estimated using logit models and were used to calculate the relative importance (RI) of each attribute. A chi-square test was used to determine the differences in preferences for the dulaglutide versus liraglutide profiles.
RESULTS: The final evaluable sample consisted of 182 participants (mean age: 58.9 [standard deviation =10.0] years; 64.3% male; mean body mass index: 26.1 [standard deviation =5.0] kg/m(2)). The RI values for the attributes in rank order were dosing frequency (44.1%), type of delivery system (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants preferred the dulaglutide profile (94.5%) compared to the liraglutide profile (5.5%; P<0.0001).
CONCLUSION: This study elicited the preferences of Japanese T2DM patients for attributes and levels representing the actual characteristics of two existing glucagon-like peptide-1 receptor agonists. In this comparison, dosing frequency and type of delivery system were the two most important characteristics, accounting for >70% of the RI. These findings are similar to those of a previous UK study, providing information about patients' preferences that may be informative for patient-clinician treatment discussions.
Verbatim abstract via PubMed 27524889 ↗